<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768974</url>
  </required_header>
  <id_info>
    <org_study_id>PB-106-003</org_study_id>
    <nct_id>NCT02768974</nct_id>
  </id_info>
  <brief_title>Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis</brief_title>
  <official_title>An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with
      active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized
      to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events following daily administration of OPRX 106</measure>
    <time_frame>70 days</time_frame>
    <description>Adverse events from subject reporting or other assessments</description>
  </primary_outcome>
  <other_outcome>
    <measure>OPRX-106 individual plasma levels following single and multiple dose administrations</measure>
    <time_frame>56 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical response or clinical remission from baseline to end of OPRX 106 treatment</measure>
    <time_frame>Baseline to day 56</time_frame>
    <description>Based on Mayo score</description>
  </other_outcome>
  <other_outcome>
    <measure>Histopathological improvement (Geboes scale) from baseline to end of OPRX treatment</measure>
    <time_frame>Baseline to day 56</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improvement from baseline to end of OPRX 106 treatment in hs-CRP levels</measure>
    <time_frame>Baseline to day 56</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improvement from baseline to end of OPRX 106 treatment in fecal calprotectin levels</measure>
    <time_frame>Baseline to day 56</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>OPRX-106 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, 1:1 randomization ration (up to 10 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPRX-106 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, 1:1 randomization ration (up to 10 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPRX-106</intervention_name>
    <description>Oral delivery, once daily.</description>
    <arm_group_label>OPRX-106 2 mg</arm_group_label>
    <arm_group_label>OPRX-106 8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Have had a diagnosis of ulcerative colitis for a minimum of 3 months

          2. Have active mild to moderate ulcerative colitis, as defined by a full Mayo score at
             screening

          3. Have adequate cardiac, renal and hepatic functions as determined by the investigator
             and demonstrated by screening clinical and laboratory evaluations, and physical
             examination results

          4. High level of calprotectin (&gt;100 mg/kg of stool)

        Main Exclusion Criteria:

          1. Have a history of colonic or rectal surgery other than hemorrhoidal surgery or
             appendectomy

          2. .Positive for active/ latent mycobacterium tuberculosis (TB) infection

          3. .Have a history of infection requiring administration of any IV antibiotic, antiviral
             or antifungal medication or any oral anti-infective agent

          4. Severe ulcerative colitis

          5. Ulcerative proctitis, defined as disease limited to less than 15 cm from the anal
             verge

          6. Use &gt;4.8 g 5-ASA or equivalent

          7. Use of corticosteroid or 5-ASA enemas, foams, or suppositories

          8. Use of anti-inflammatory medications or natural remedies

          9. Use oral or parenteral antibiotics

         10. Use of chronic non-steroidal anti-inflammatory (NSAID) therapy

         11. Use of immune suppressive agents including anti-TNF agents, Azathioprine, 6MP,
             Methotrexate

         12. Use of steroids

         13. Have a diagnosis of: Crohn's disease; Indeterminate colitis; Microscopic colitis;
             Ischemic or infectious colitis; Clostridium difficile colitis, Parasitic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Dekel, DVM</last_name>
    <role>Study Director</role>
    <affiliation>Sr. Director Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einat Dekel, DVM</last_name>
    <email>Einat.Dekel@protalix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka University Hospital</name>
      <address>
        <city>Be'er-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Fich, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattitiahu Waterman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eran Israeli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare-Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eran Goldin, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wisam Sbeit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Rishon Lezion</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haim Shirin, MD, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigal Fishman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

